Pediatrix reaffirms FY 2026 Adjusted EBITDA guidance of $280M-$300M; payor mix stable

Pediatrix Medical Group, Inc.

Payor mix for Q2 2026 remained stable and unchanged relative to recent historical trends and internal expectations.
Company has not experienced unfavorable payor mix shifts reported elsewhere in healthcare sector.
Reaffirms full year 2026 Adjusted EBITDA outlook in range of $280 million to $300 million.
No material changes in other net revenue-related trends compared to recent historical periods.
Earnings conference call scheduled for August 4, 2026 at 9:00 a.m. ET to discuss Q2 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.